As a perspective, our model of dMMR CRC originating from epigenetic silencing of MLH1 by promoter hypermethylation provides a unique opportunity to investigate the impact of FDA-approved methyl transferase inhibitors such as azacytidine or decitabine. The gene discussed is MLH1; the disease is colorectal carcinoma.